日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細


公開

学術論文

Comprehensive Evaluation of Rapamycin’s Specificity as an mTOR Inhibitor

MPS-Authors
/persons/resource/persons285163

Artoni,  F.
Demetriades – Cell Growth Control in Health and Age-related Disease, Max Planck Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society;

/persons/resource/persons284253

Grützmacher,  N.
Demetriades – Cell Growth Control in Health and Age-related Disease, Max Planck Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society;

/persons/resource/persons278102

Demetriades,  C.
Demetriades – Cell Growth Control in Health and Age-related Disease, Max Planck Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society;

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
フルテキスト (公開)
公開されているフルテキストはありません
付随資料 (公開)
There is no public supplementary material available
引用

Artoni, F., Grützmacher, N., & Demetriades, C. (2022). Comprehensive Evaluation of Rapamycin’s Specificity as an mTOR Inhibitor. bioRxiv, 2022.12.10.519872. doi:10.1101/2022.12.10.519872.


引用: https://hdl.handle.net/21.11116/0000-000C-31FC-1
要旨
Rapamycin is a macrolide antibiotic that functions as an immunosuppressive and anti-cancer agent, and displays robust anti-ageing effects in multiple organisms including humans. Importantly, rapamycin analogs (rapalogs) are of clinical importance against certain cancer types and neurodevelopmental diseases. Although rapamycin is widely perceived as an allosteric inhibitor of mTOR (mechanistic target of rapamycin), the master regulator of cellular and organismal physiology, its specificity has not been thoroughly evaluated so far. In fact, previous studies in cells and in mice suggested that rapamycin may be also acting independently from mTOR to influence various cellular functions. Here, we generated a gene-edited cell line, that expresses a rapamycin-resistant mTOR mutant (mTORRR), and assessed the effects of rapamycin treatment on the transcriptome and proteome of control or mTORRR-expressing cells. Our data reveal a striking specificity of rapamycin towards mTOR, demonstrated by virtually no changes in mRNA or protein levels in rapamycin-treated mTORRR cells, even following prolonged drug treatment. Overall, this study provides the first comprehensive and conclusive assessment of rapamycin’s specificity, with important potential implications for ageing research and human therapeutics.Competing Interest StatementThe authors have declared no competing interest.